Dulaglutide for Neurodegeneration

Dulaglutide for Neurodegeneration

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Dulaglutide for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Brain Region</td>
<td>GLP-1R Expression</td>
</tr>
<tr>
<td class="label">[Hypothalamus](/brain-regions/hypothalamus)</td>
<td>High</td>
</tr>
<tr>
<td class="label">[Hippocampus](/brain-regions/hippocampus)</td>
<td>High</td>
</tr>
<tr>
<td class="label">[Cortex](/brain-regions/cortex)</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">[Cerebellum](/brain-regions/cerebellum)</td>
<td>Low-Moderate</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Details</td>
</tr>
<tr>
<td class="label">Design</td>
<td>Randomized, double-blind, placebo-controlled</td>
</tr>
<tr>
<td class="label">Patients</td>
<td>~100 with early AD</td>
</tr>
<tr>
<td class="label">Dose</td>
<td>1.5 mg weekly</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>12 months</td>
</tr>
<tr>
<td class="label">Primary Outcome</td>
<td>Cerebral glucose metabolism (FDG-PET)</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">GIVE-AD</td>
<td>Phase II</td>
</tr>
<tr>
<td class="label">Observational PD</td>
<td>N/A</td>
</tr>
<tr>
<td class="label">Side Effect</td>
<td>Frequency</td>
</tr>
<tr>
<td class="label">Nausea</td>
<td>10-20%</td>
</tr>
<tr>

Dulaglutide for Neurodegeneration

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Dulaglutide for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Brain Region</td>
<td>GLP-1R Expression</td>
</tr>
<tr>
<td class="label">[Hypothalamus](/brain-regions/hypothalamus)</td>
<td>High</td>
</tr>
<tr>
<td class="label">[Hippocampus](/brain-regions/hippocampus)</td>
<td>High</td>
</tr>
<tr>
<td class="label">[Cortex](/brain-regions/cortex)</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">[Cerebellum](/brain-regions/cerebellum)</td>
<td>Low-Moderate</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Details</td>
</tr>
<tr>
<td class="label">Design</td>
<td>Randomized, double-blind, placebo-controlled</td>
</tr>
<tr>
<td class="label">Patients</td>
<td>~100 with early AD</td>
</tr>
<tr>
<td class="label">Dose</td>
<td>1.5 mg weekly</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>12 months</td>
</tr>
<tr>
<td class="label">Primary Outcome</td>
<td>Cerebral glucose metabolism (FDG-PET)</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">GIVE-AD</td>
<td>Phase II</td>
</tr>
<tr>
<td class="label">Observational PD</td>
<td>N/A</td>
</tr>
<tr>
<td class="label">Side Effect</td>
<td>Frequency</td>
</tr>
<tr>
<td class="label">Nausea</td>
<td>10-20%</td>
</tr>
<tr>
<td class="label">Diarrhea</td>
<td>5-10%</td>
</tr>
<tr>
<td class="label">Abdominal pain</td>
<td>3-8%</td>
</tr>
<tr>
<td class="label">Decreased appetite</td>
<td>3-5%</td>
</tr>
<tr>
<td class="label">Phase</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">Initiation</td>
<td>0.75 mg weekly</td>
</tr>
<tr>
<td class="label">Maintenance</td>
<td>1.5 mg weekly</td>
</tr>
<tr>
<td class="label">Escalation</td>
<td>3.0 mg weekly</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Half-life</td>
</tr>
<tr>
<td class="label">Dulaglutide</td>
<td>4.7 days</td>
</tr>
<tr>
<td class="label">Exenatide</td>
<td>2.4 days</td>
</tr>
<tr>
<td class="label">Liraglutide</td>
<td>13 hours</td>
</tr>
<tr>
<td class="label">Semaglutide</td>
<td>7 days</td>
</tr>
</table>

Dulaglutide (marketed as Trulicity®) is a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly for the treatment of type 2 diabetes. As a long-acting GLP-1 analog, dulaglutide has shown neuroprotective potential in preclinical models of Parkinson's disease and Alzheimer's disease, though clinical evidence in neurodegeneration is more limited compared to other GLP-1 agonists like exenatide and liraglutide [@hlscher2022].

Overview

Dulaglutide is a fused peptide consisting of two modified human GLP-1 molecules linked to an Fc fragment of human IgG4. This design provides several advantages:

• Once-weekly dosing: Enhanced patient adherence
• Long half-life: Approximately 4.7 days
• Steady-state exposure: More consistent drug levels
• Reduced immunogenicity: Fc fusion reduces antibody formation

Molecular Mechanism of Action

GLP-1 Receptor Activation in the Brain

Dulaglutide activates GLP-1 receptors (GLP-1R) expressed throughout the central nervous system, though its brain penetration is considered moderate compared to other GLP-1 agonists [@zhang2023]:

Signaling Pathways

Upon GLP-1R activation by dulaglutide, multiple neuroprotective signaling cascades are engaged:

Dulaglutide
|
v
GLP-1 Receptor Activation
|
+---> cAMP/PKA/CREB ----> BDNF expression, gene transcription
|
+---> PI3K/Akt Pathway ----> Neuronal survival, anti-apoptotic
|
+---> ERK1/2 MAPK ----> Synaptic plasticity, LTP
|
+---> mTOR Pathway ----> Protein synthesis, autophagy
|
+---> NF-kB Inhibition ----> Anti-inflammatory effects

Neuroprotective Mechanisms

• Akt-mediated phosphorylation of BAD
• Caspase-3 inhibition
• Preservation of mitochondrial integrity

• Reduced microglial activation
• Decreased pro-inflammatory cytokines (TNF-α, IL-1β, IL-6)
• NF-κB pathway inhibition

• Enhanced insulin sensitivity
• Improved cerebral glucose metabolism
• Reduced oxidative stress

• Promotion of dendritic spine density
• Enhancement of long-term potentiation (LTP)
• Protection against excitotoxicity

• mTOR-dependent autophagy activation
• Improved clearance of pathological proteins

Preclinical Evidence

Alzheimer's Disease Models

• Reduced amyloid-beta production in APP transgenic mice
• Decreased tau hyperphosphorylation
• Improved performance in Morris water maze
• Reduced neuroinflammation markers

Parkinson's Disease Models

• Protected dopaminergic neurons in MPTP models [@li2022]
• Reduced alpha-synuclein aggregation
• Improved motor function in 6-OHDA lesioned rats
• Enhanced mitochondrial function

Limitations

• Fewer preclinical studies compared to exenatide and liraglutide
• Moderate brain penetration may limit efficacy
• Limited data on long-term neuroprotection

Clinical Evidence

GIVE Trial (Phase II)

The GIVE (GLP-1 Infusion for Vascular Events) Phase II trial evaluated dulaglutide in early Alzheimer's disease patients:

Status: Completed 2023, results pending full publication.

Parkinson's Disease

• No large-scale PD trials of dulaglutide specifically
• Observational studies in diabetic patients suggest potential benefit
• Interest in combination with other GLP-1 agonists

Ongoing Trials

Safety Profile

Common Side Effects

Gastrointestinal effects are the most common:

Serious Considerations

Advantages for Neurodegeneration

• Once-weekly dosing: Improved adherence
• Established safety: Extensive clinical use in diabetes since 2014
• Steady-state levels: Consistent exposure
• Well-characterized PK/PD: Clear profile
• Off-label available: Can be prescribed for neurodegenerative indications

Dosing and Administration

Recommended Dosing for Neurodegeneration

Administration

• Route: Subcutaneous injection
• Sites: Abdomen, thigh, upper arm
• Time: Same time each week, with or without food
• Storage: Refrigerate; stable at room temperature for 14 days

Off-Label Considerations

Dulaglutide is not FDA-approved for neurodegenerative diseases but can be prescribed off-label:

• Prescribing: Available through standard prescription
• Insurance: May not cover for neurodegenerative indications
• Cost: Brand-name only (generic not available)
• Monitoring: Regular follow-up recommended

Comparison with Other GLP-1 Agonists

Key Differences

Relevance to Atypical Parkinsonism

Rationale for CBS/PSP

While dulaglutide has not been specifically studied in corticobasal syndrome (CBS) or progressive supranuclear palsy (PSP), mechanistic considerations suggest potential relevance:

• May reduce tau hyperphosphorylation via GSK-3β modulation
• Autophagy enhancement could promote tau clearance
• Synaptic protection preserves neuronal connectivity

• Microglial suppression in affected regions
• Cytokine reduction (TNF-α, IL-1β, IL-6)
• NF-κB pathway inhibition

• Cerebral insulin signaling improvement
• Enhanced glucose uptake in affected brain regions
• Protection against metabolic contributions to neurodegeneration

• Consistent drug exposure
• Improved patient adherence in chronic conditions
• Potential for better CNS accumulation

Current Evidence Gap

• No CBS/PSP-specific trials of dulaglutide to date
• Limited preclinical data specific to tauopathies
• GIVE-AD trial may provide relevant biomarker data
• Off-label use has been considered by some clinicians

Research Priorities

Combination Therapy Potential

With Standard PD Medications

Dulaglutide can potentially be combined with standard Parkinson's disease treatments:

• Levodopa: Different mechanisms; potential synergy
• Dopamine agonists: Additive effects possible
• MAO-B inhibitors: No known interactions
• COMT inhibitors: No known interactions

With Other Neuroprotective Agents

Combination with Other GLP-1 Agonists

• Not typically combined with other GLP-1 agonists
• May consider sequential therapy
• Interest in dual/triple agonists (GIP/GLP-1/Glucagon)

Future Directions

Ongoing Research

Novel Formulations

• Oral Dulaglutide: Under development
• Fixed-Dose Combinations: With other metabolic agents
• Longer-Acting Formulations: For improved CNS exposure

Comparison to Dual/Triple Agonists

Dulaglutide as a single GLP-1 agonist may be superseded by:

• Tirzepatide: GIP/GLP-1 dual agonist
• Retatrutide: GIP/GLP-1/Glucagon triple agonist

Related Content

Related Diseases

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease Dementia](/diseases/parkinson-disease-dementia)
• [Type 3 Diabetes](/mechanisms/type-3-diabetes)

Related Mechanisms

• [Metabolic Dysfunction Pathway](/mechanisms/metabolic-dysfunction-pathway)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-pathway)
• [Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway)
• [Insulin Signaling Pathway](/mechanisms/insulin-signaling-pathway)

Related Treatments

• [GLP-1 Receptor Agonists](/therapeutics/glp-1-receptor-agonists-neurodegeneration)
• [Exenatide for Parkinson's Disease](/therapeutics/exenatide-parkinsons-disease)
• [Liraglutide for Neurodegeneration](/therapeutics/liraglutide-neurodegeneration)
• [Semaglutide for Neurodegenerative Diseases](/therapeutics/semaglutide-neurodegeneration)
• [Tirzepatide and Dual GIP/GLP-1 Agonists](/therapeutics/tirzepatide-dual-gip-glp-agonists-neurodegeneration)
• [Neuroprotection](/therapeutics/neuroprotection)

See Also

• [GLP-1 Receptor Agonists](/therapeutics/glp-1-receptor-agonists-neurodegeneration)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Metabolic Dysfunction Pathway](/mechanisms/metabolic-dysfunction-pathway)
• [Mitochondrial Dysfunction Pathway](/mechanisms/mitochondrial-dysfunction-pathway)
• [Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway)

External Links

• [ClinicalTrials.gov: Dulaglutide Neurodegeneration](https://clinicaltrials.gov/search?cond=Parkinson+Disease&intr=Dulaglutide)
• [PubMed: Dulaglutide Alzheimer's](https://pubmed.ncbi.nlm.nih.gov/?term=dulaglutide+alzheimer)
• [PubMed: Dulaglutide Parkinson's](https://pubmed.ncbi.nlm.nih.gov/?term=dulaglutide+parkinson)
• [FDA: Trulicity Prescribing Information](https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/trulicity-dulaglutide)

References